USPTO Patents Application 09639859

In The Claims

1-44. (cancelled)

45. (currently amended) An anabolic medicament for treating a damaged tissue, th e tissu e
b e ing charact e riz e d, wh e n h e althy, by a charact e ristic amino acid molar ratio for th e h e althy
tissu e p e r s e , or for at l e ast on e p e ptid e , polyp e ptid e , or prot e in th e r e of, the medicament
comprising:

a) at least one mucopolysaccharide extracellular matrix compound in an amount effective
in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,

b) at least one polar surface active lipid; and

c) at l e ast a plurality of amino acids having an alpha carbon, the amino acids being
present at a molar ratio which is characteristic of human breast tissue protein
corr e sponding to th e charact e ristic amino acid molar ratio , and wherein no more than
10% of the amino acid s are b e ing in d e xtorotary D-form.

46. (previously presented) The medicament according to claim 45, wherein said extracellular
matrix compound is synthetically produced.

47. (previously presented) The medicament according to claim 45, wherein said extracellular
matrix compound is obtained from a cellular or tissue source.

48. (previously presented) The medicament according to claim 45, wherein said polar surface
active lipid is obtained from a cellular or tissue source.

49. (previously presented) The medicament according to claim 45, wherein said polar
surface active lipid is synthetically produced.

50. (currently amended) The medicament according to claim 45, wherein at l e ast on e of
said amino acids is are synthetically produced.

~PHILl:3677666.vl 9

5 1 . (currently amended) The medicament according to claim 45, wherein said at l e ast one
of said amino acids is are obtained from a cellular or tissue source.

52. (previously presented) The medicament according to claim 47, wherein said cellular or
tissue source is selected from the group consisting of a cell membrane, a tissue and organ.

53. (previously presented) The medicament according to claim 45, wherein said extracellular
matrix compound is selected from the group consisting of a glucosaminoglycan, a collagen,
cartilage, chondroitin sulfate, a glycoprotein, and a protoglycan.

54. (previously presented) The medicament according to claim 45, wherein said polar surface
active lipid is selected from the group consisting of a phosho lipid, a glycolipid, and a lipoprotein.

55. -58. (canceled)

59. (currently amended) The medicament according to claim #£101, further comprising
amino acids pr e s e nt at a molar ratio corr e sponding to a charact e ristic molar ratio of amino acids
in cyclosporin methionine or betaine .

60. (currently amended) The medicament according to claim 59, wherein said medicament
further comprises amino acids pr e s e nt at th e molar ratio corr e sponding to th e charact e ristic molar
ratio of amino acids in cyclosporin are glycine , L alanin e , L l e ucin e , and L valin e.

61. -64. (canceled)

65. (previously presented) The medicament according to claim 45, further comprising a
sterile vehicle.

~PHILl:3677666.vl

3

66. (previously presented) The medicament according to claim 48, wherein said cellular or
tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.

67. (previously presented) The medicament according to claim 51, wherein said cellular or
tissue source is selected from the group consisting of a cell membrane, a tissue, and an organ.

68. (previously presented) The medicament according to claim 49, wherein said polar
surface active lipid is selected from a group consisting of a phosholipid, a glycolipid, and a
lipoprotein.

69. (previously presented) The medicament according to claim 48, wherein said polar
surface active lipid is selected from the group consisting of a phosholipid, a glycolipid, and
lipoprotein.

70. (previously presented) The medicament according to claim 48, wherein at least one
extracellular matrix compound, at least one polar surface active lipid, and at least one amino acid
associate through a molecular bonding force.

71 . (previously presented) The medicament according to claim 70, wherein said molecular
bonding force is selected from the group consisting of electron affinity, van der Waals, and
zwitterionic.

72. (previously presented) The medicament according to claim 59, wherein components of
said medicament associate through a molecular bonding force.

~PHILl:3677666.vl

4

73. (previously presented) The medicament according to claim 70, wherein said molecular
bonding force is selected from the group consisting of electron affinity, van der Waals, and
zwitterionic.

74. (previously presented) The medicament according to claim 45 further comprising at least
one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3
oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j)
collagen.

75. (currently amended) The medicament according to claim #9 101 , further comprising at
least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d)
omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and
(j) collagen.

76. (previously presented) The medicament according to claim 48, further comprising at least
one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3
oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j)
collagen.

77. (previously presented) The medicament according to claim 73, further comprising at
least one of (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d)
omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and
(j) collagen.

78-96. (cancelled)

~PHILl:3677666.vl

5

97. (currently amended) The medicament according to claim 45 x wh e r e in said further
comprising an amino acid is s e l e ct e d from th e group consisting of L alanin e , L arginin e , L
asparagin e , L - cyst e in e , L glutamic acid, L glutamino, L glutamat e , L prolin e , L s e rin e , glycin e ,
L - thr e onin e , L tyrosin e , L taurin e , L- gamma amino butyric acidraad or L-carnitine.

98. (currently amended) The medicament according to claim 45 further comprising a fatty
acid selected from the group consisting of linoleic acid er and linolenic acid.

99. (currently amended) The medicament according to claim 45 101, wherein the amino
acids are present in a ratio of four moles L-leucine: two moles L-alanine: two moles L- valine:
one mole methionine: one mole [[L-]]gamma amino butyric acid: one mole [[L-]]betaine: one
mole glycine.

100. (currently amended) The medicament according to claim 99, further comprising a fatty
acid selected from the group consisting of linoleic acid er and linolenic acid.

101. (previously presented) An anabolic medicament for treating a damaged tissue, the
medicament comprising:

a) at least one mucopolysaccharide extracellular matrix compound in an amount effective
in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,

b) at least one polar surface active lipid; and

c) a plurality of amino acids having an alpha carbon, the amino acids being present at a
molar ratio which is characteristic of cyclosporin, wherein no more than 10% of the amino acids
are in D-form, and the molar ratio comprises 2 moles L-valine: 4 moles L-leucine: 2-moles L-
alanine.

102. (previously presented) An anabolic medicament for treating a damaged tissue, the
medicament comprising:

~PHILl:3677666.vl

6

a) at least one mucopolysaccharide extracellular matrix compound in an amount effective
in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,

b) at least one polar surface active lipid; and

c) a plurality of amino acids having an alpha carbon, the amino acids being present at a
molar ratio which is characteristic of healthy skin, wherein no more than 10% of the amino acids
are in D-form, and the molar ratio of L-amino acids is 3 moles L-methionine: 16 moles L-
proline: 13 moles L-tyrosine: 30 moles L-asparagine: 8 moles L-phenylalanine: 20 moles L-
cysteine: 50 moles L-leucine: 38 moles L-serine: 29 moles L-arginine: 21 moles L-threonine: 21
moles L- valine: 3 moles L-histidine: 22 moles L-alanine: 14 moles L-isoleucine: 2 moles L-
tryptophan: 46 moles L-glutamic acid: 12 moles L-lysine: 14 moles L-aspartic acid: 32 moles of
L-glutamine.

103. (previously presented) An anabolic medicament for treating a damaged tissue, the
medicament comprising:

a) at least one mucopolysaccharide extracellular matrix compound in an amount effective
in the damaged tissue as anti-neo-inflammatory and anti-neo-angiogenetic agent,

b) at least one polar surface active lipid; and

c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar
ratio which is characteristic of fibrinogen, wherein no more than 10% of the amino acids are in D-
form, and the molar ratio of L-amino acids is 15 moles L-methionine: 41 moles L-proline: 24 moles
L-tyrosine: 30 moles L-asparagine: 28 moles L-phenylalanine: 13 moles L-cysteine: 51 moles L-
leucine: 107 moles L-serine: 54 moles L-arginine: 59 moles L-threonine: 45 moles L- valine: 19
moles L-histidine: 37 moles L-alanine: 26 moles L-isoleucine: 19 moles L-tryptophan: 64 moles L-
glutamic acid: 42 moles L-lysine: 50 moles L-aspartic acid: 30 moles L-glutamine.

104. (new) The medicament of claim 45, wherein the damaged tissue is selected from the
group consisting of skin, eye, liver, gastro-intestinal, kidney, and lung.

~PHILl:3677666.vl

7

105. (new) The medicament of claim 104, wherein the gastro-intestinal tissue is bowel

tissue.

106. (new) The medicament of claim 105, wherein the bowel tissue is damaged from
regional ileitis (Crohn's Disease), inflammatory bowel disease, ulcerative colitis, or mucous colitis.

~PHILl:3677666.vl

8